List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3328009/publications.pdf Version: 2024-02-01



IIIS DAZ-AD

#	Article	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	27.0	7,973
2	Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 1919-1929.	27.0	3,261
3	Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2040-2051.	27.0	2,676
4	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 2018, 378, 2093-2104.	27.0	2,469
5	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 2018, 379, 2342-2350.	27.0	2,150
6	First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2415-2426.	27.0	2,145
7	Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	27.0	1,866
8	Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	13.7	1,274
9	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
10	First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, The, 2017, 389, 917-929.	13.7	919
11	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	10.7	773
12	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and) Tj ETQq0	0 OlngBT /(Dv edo ck 10 T
13	Current Challenges in Cancer Treatment. Clinical Therapeutics, 2016, 38, 1551-1566.	2.5	549
14	First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology, 2019, 37, 992-1000.	1.6	457
15	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology, 2018, 29, i10-i19.	1.2	449
16	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1301-1311.	1.6	445
17	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 2017, 28, 270-277.	1.2	425
18	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	10.7	418

#	Article	IF	CITATIONS
19	A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 2020, 15, 1657-1669.	1.1	395
20	Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 51-65.	10.7	356
21	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology, 2020, 15, 288-293.	1.1	328
22	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. Journal of Thoracic Oncology, 2021, 16, 860-867.	1.1	323
23	A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 730-738.	7.0	265
24	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncology, The, 2020, 21, 645-654.	10.7	247
25	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology, 2017, 35, 412-420.	1.6	237
26	KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer, 2018, 124, 53-64.	2.0	232
27	Association of <i>EGFR</i> L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 2015, 1, 149.	7.1	224
28	First-in-Human Dose Study of the Novel Transforming Growth Factor-Î ² Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research, 2015, 21, 553-560.	7.0	199
29	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	10.7	193
30	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer, 2008, 98, 1608-1613.	6.4	155
31	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 165-183.	1.1	134
32	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Annals of Oncology, 2020, 31, 798-806.	1.2	131
33	Clinical outcomes in nonâ€smallâ€cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis. Journal of Cellular and Molecular Medicine, 2010, 14, 51-69.	3.6	126
34	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1210-1222.	1.1	119
35	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947.	1.1	119
36	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113

#	Article	IF	CITATIONS
37	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	2.8	112
38	Clinicopathologic Features of Advanced Squamous NSCLC. Journal of Thoracic Oncology, 2016, 11, 1411-1422.	1.1	101
39	Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial. Journal of Thoracic Oncology, 2015, 10, 1745-1753.	1.1	100
40	Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, 2022, 7, 100408.	4.5	94
41	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of Thoracic Oncology, 2021, 16, 1883-1892.	1.1	93
42	MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. European Respiratory Journal, 2014, 43, 1740-1749.	6.7	91
43	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open, 2021, 6, 100273.	4.5	91
44	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
45	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 2020, 151, 102978.	4.4	79
46	SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. European Journal of Cancer, 2020, 135, 242-250.	2.8	74
47	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, LBA109-LBA109.	1.6	74
48	ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncology, 2019, 15, 231-239.	2.4	69
49	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PDâ€L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer, 2020, 126, 4867-4877.	4.1	69
50	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. JAMA Oncology, 2020, 6, 100.	7.1	68
51	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	2.5	65
52	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 2019, 30, 161-165.	1.2	60
53	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 989-1003.	2.4	59
54	Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 271-280.	1.6	59

#	Article	IF	CITATIONS
55	Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. Journal of Clinical Oncology, 2022, 40, 671-680.	1.6	59
56	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. PLoS ONE, 2014, 9, e107200.	2.5	58
57	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 2018, 19, e465-e479.	2.6	56
58	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p> . Cancer Management and Research, 2019, Volume 11, 10463-10476.	1.9	56
59	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Annals of Oncology, 2019, 30, 290-296.	1.2	55
60	Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open, 2022, 7, 100399.	4.5	54
61	FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. Journal of Thoracic Oncology, 2019, 14, 641-655.	1.1	50
62	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer, 2019, 108, 120-128.	2.8	50
63	Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy, Clinical Lung Cancer, 2016, 17, 80-84.	2.6	45
64	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Annals of Oncology, 2010, 21, 195-198.	1.2	41
65	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer, 2017, 112, 181-187.	2.0	40
66	Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. Oncologist, 2018, 23, 1092-1102.	3.7	38
67	Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clinical Lung Cancer, 2019, 20, e601-e608.	2.6	38
68	Biological therapies in nonsmall cell lung cancer. European Respiratory Journal, 2017, 49, 1601520.	6.7	37
69	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs, 2012, 30, 729-740.	2.6	36
70	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Frontiers in Oncology, 2020, 10, 578756.	2.8	36
71	A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous nonâ€small cell lung cancer. Lung Cancer, 2017, 108, 212-216.	2.0	35
72	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung Cancer, 2019, 134, 245-253.	2.0	35

#	Article	IF	CITATIONS
73	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology, 2021, 16, 289-298.	1.1	35
74	Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced <i>ALK</i> -rearranged non-small cell lung cancer. European Respiratory Journal, 2018, 51, 1702431.	6.7	32
75	PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Annals of Oncology, 2019, 30, v928-v929.	1.2	32
76	Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 418-425.	2.6	31
77	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1569-1579.	2.5	31
78	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer, 2021, 151, 30-38.	2.0	30
79	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
80	Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11, 572-579.	2.4	28
81	Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncology, 2019, 15, 705-716.	2.4	28
82	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 2020, 149, 46-52.	2.0	28
83	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 8009-8009.	1.6	27
84	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer, 2014, 50, 496-505.	2.8	26
85	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer, 2019, 133, 10-19.	2.0	25
86	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Annals of Oncology, 2018, 29, 1701-1709.	1.2	24
87	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer, 2019, 134, 72-78.	2.0	24
88	Immunologic Checkpoint Blockade in Lung Cancer. Seminars in Oncology, 2015, 42, 402-417.	2.2	23
89	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE, 2019, 14, e0221994.	2.5	23
90	LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology, 2020, 31, S1212-S1213.	1.2	23

#	Article	IF	CITATIONS
91	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271.	7.0	23
92	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLoS ONE, 2015, 10, e0119878.	2.5	23
93	Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 198-206.	2.6	22
94	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
95	Durvalumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880415.	3.2	22
96	PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial. Journal of Thoracic Oncology, 2021, 16, S844-S845.	1.1	22
97	First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. ESMO Open, 2021, 6, 100003.	4.5	21
98	Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2009, 27, e19048-e19048.	1.6	20
99	Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 2018, 379, 1093-1094.	27.0	18
100	Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. Lung Cancer, 2022, 167, 41-48.	2.0	18
101	Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain. ESMO Open, 2020, 5, e000828.	4.5	17
102	Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open, 2021, 6, 100113.	4.5	17
103	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clinical Lung Cancer, 2018, 19, 331-339.	2.6	15
104	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	6.1	15
105	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2009, 11, 284-289.	2.4	14
106	Reflexiones sobre la implementación del cribado mediante tomografÃa computarizada de baja dosis en personas con riesgo elevado de padecer cáncer de pulmón en España. Archivos De Bronconeumologia, 2017, 53, 568-573.	0.8	14
107	Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 522-528.	2.3	13
108	Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. Clinical Lung Cancer, 2017, 18, 667-674.e1.	2.6	13

#	Article	IF	CITATIONS
109	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer, 2018, 19, 213-220.e4.	2.6	13
110	Lurbinectedin in the treatment of relapsed small cell lung cancer. Future Oncology, 2021, 17, 2279-2289.	2.4	13
111	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non‒Small-Cell Lung Cancer in KEYNOTE-407. JTO Clinical and Research Reports, 2021, 2, 100225.	1.1	13
112	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, LBA109-LBA109.	1.6	13
113	458â€First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC). , 2021, 9, A486-A487.		13
114	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer, 2019, 131, 112-121.	2.0	12
115	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer, 2019, 20, e407-e412.	2.6	12
116	A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). Journal of Clinical Oncology, 2004, 22, 3543-3543.	1.6	12
117	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. Frontiers in Medicine, 2017, 4, 36.	2.6	11
118	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology, 2019, 3, 1-13.	3.0	11
119	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clinical and Translational Oncology, 2020, 22, 759-771.	2.4	11
120	Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. Cancer Research, 2018, 78, CT077-CT077.	0.9	11
121	30 Immunotherapy in advanced NSCLC—from the â€~tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2018, 3, e000298.	4.5	10
122	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncology, 2019, 15, 1363-1383.	2.4	10
123	Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open, 2022, 7, 100410.	4.5	10
124	Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non–Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. Clinical Lung Cancer, 2018, 19, 65-73.e7.	2.6	9
125	First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. International Journal of Clinical Oncology, 2021, 26, 1073-1082.	2.2	9
126	Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid. Journal of Thrombosis and Thrombolysis, 2022, 53, 471-478.	2.1	8

#	Article	IF	CITATIONS
127	MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. Journal of Thoracic Oncology, 2021, 16, S939.	1.1	8
128	Treatment for early-stage lung cancer: what next?. Lancet, The, 2014, 383, 1528-1530.	13.7	7
129	Second-Line Treatment Options in Non–Small-CellÂLung Cancer: Report From anÂInternational Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	2.6	7
130	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	2.4	7
131	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies Journal of Clinical Oncology, 2016, 34, e20522-e20522.	1.6	7
132	Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?. Translational Lung Cancer Research, 2016, 5, 95-7.	2.8	7
133	Lung Cancer and Microbiome. Archivos De Bronconeumologia, 2020, 56, 3-4.	0.8	6
134	OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial. Journal of Thoracic Oncology, 2021, 16, S127.	1.1	6
135	A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). Journal of Clinical Oncology 2004 22, 3543-3543	1.6	6
136	Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 8055-8055.	1.6	6
137	RESILIENT part 1: A phase 2 doseâ€exploration and doseâ€expansion study of secondâ€line liposomal irinotecan in adults with small cell lung cancer. Cancer, 2022, , .	4.1	5
138	Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Medical Oncology, 2016, 33, 105.	2.5	3
139	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clinical and Translational Oncology, 2017, 19, 219-226.	2.4	3
140	Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC). Journal of Clinical Oncology, 2006, 24, 7084-7084.	1.6	3
141	Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling Journal of Clinical Oncology, 2014, 32, TPS8120-TPS8120.	1.6	3
142	Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy. Nanoscale, 2022, 14, 8028-8040.	5.6	3
143	Osimertinib in EGFR -mutant NSCLC: how to select patients and when to treat. Lancet Oncology, The, 2016, 17, 1622-1623.	10.7	2
144	Foreword to †The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'. British Journal of Cancer, 2020, 123, 1-2.	6.4	2

#	Article	IF	CITATIONS
145	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncology, 2021, 17, 1165-1184.	2.4	2
146	Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial Journal of Clinical Oncology, 2022, 40, 8524-8524.	1.6	2
147	Inmunoterapia en el cáncer: grandes expectativas en el mundo de la oncologÃa, pero un motivo de preocupación renal. Nefrologia, 2019, 39, 94-96.	0.4	1
148	Combination treatment options for small-cell lung cancer – Authors' reply. Lancet Oncology, The, 2021, 22, e84.	10.7	1
149	Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study. , 2021, , .		1
150	A phase Ib study of abemaciclib in combination with multiple single agents in stage IV NSCLC Journal of Clinical Oncology, 2015, 33, 8047-8047.	1.6	1
151	Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study Journal of Clinical Oncology, 2015, 33, e19024-e19024.	1.6	1
152	A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2016, 34, TPS9107-TPS9107.	1.6	1
153	Between Bench and Bed Side: PI3K Inhibitors. Current Molecular Pharmacology, 2010, 3, 79-90.	1.5	1
154	Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institucion experience Journal of Clinical Oncology, 2015, 33, e11570-e11570.	1.6	1
155	P37â€Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer. , 2019, , .		1
156	Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Pneumologie, 2020, 74, .	0.1	1
157	Summary of â€~The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'. British Journal of Cancer, 2020, 123, 36-36.	6.4	Ο
158	Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC. Journal of Thoracic Oncology, 2021, 16, e24.	1.1	0
159	Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Journal of Clinical Oncology, 2004, 22, 8037-8037.	1.6	0
160	GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC Journal of Clinical Oncology, 2012, 30, 7544-7544.	1.6	0
161	Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third) Tj ETQq1 1	0.784314	rgBJ /Overloc
162	pERK as a new prognostic factor in resected, early-staged, non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, e18501-e18501.	1.6	0

#	Article	IF	CITATIONS
163	CheckMate 817: Safety of flat-dose nivolumab (nivo) plus weight-based ipilimumab (ipi) for the first lie (1 L) treatment of advanced non-small cell lung cancer (NSCLC). Pneumologie, 2019, 73, .	0.1	о
164	CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC). , 2020, 74, .		0
165	Envolving treatment of fever and neutropenia in cancer patients. , 2002, 4, 297-307.		о
166	Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Journal of Clinical Oncology, 2004, 22, 8037-8037.	1.6	0
167	Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform. Scientific Reports, 2022, 12, 8342.	3.3	0
168	Abstract 1245: Comprehensive analysis of non-small cell lung cancer identifies molecular genotype-immunophenotype associations and candidate biomarkers predictive of response to immunotherapy. Cancer Research, 2022, 82, 1245-1245.	0.9	0
169	Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of PDX and PDX-derived organoids. Cancer Research, 2022, 82, 3101-3101.	0.9	0
170	Abstract 414: Comprehensive molecular characterization of mechanisms involved in primary resistance to EGFR tyrosine kinase inhibitors. Cancer Research, 2022, 82, 414-414.	0.9	0